Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma
- PMID: 22287594
- DOI: 10.1136/gutjnl-2011-301862
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma
Abstract
Background and aims: Conventional pathological analysis fails to achieve sufficient sensitivity and specificity for the diagnosis of hepatocellular carcinoma (HCC) in small nodules. Immunohistochemical staining for glypican 3 (GPC3), heat shock protein 70 (HSP70) and glutamine synthetase (GS) has been suggested to allow a confident diagnosis but no prospective study has established the diagnostic accuracy of this approach. The aim of this study is to assess prospectively the diagnostic accuracy of a panel of markers (GPC3, HSP70, GS) for the diagnosis of HCC in patients with cirrhosis with a small (5-20 mm) nodule detected by ultrasound screening.
Methods: Sixty patients with cirrhosis with a single nodule 5-20 mm newly detected by ultrasound were included in the study. Contrast-enhanced ultrasound, magnetic resonance and fine needle biopsy of the nodule (gold standard) were performed; the biopsy was repeated in case of diagnostic failures. Three consecutive sections of the first biopsy sample with meaningful material were stained with antibodies against GPC3, HSP70 and GS.
Results: Forty patients were diagnosed with HCC. The sensitivity and specificity for HCC diagnosis were: GPC3 57.5% and 95%, HSP70 57.5% and 85%, GS 50% and 90%, respectively. The sensitivity and specificity of the different combinations were: GPC3+HSP70 40% and 100%; GPC3+GS 35% and 100%; HSP70+GS 35% and 100%; GPC3+HSP70+GS 25% and 100%. When at least two of the markers were positive (regardless of which), the sensitivity and specificity were 60% and 100%, respectively. Conventional pathological analysis yielded three false negative results, but the addition of this panel only correctly classified one of these cases as HCC.
Conclusion: These data within a prospective study establish the clinical usefulness of this panel of markers for the diagnosis of early HCC. However, the panel only slightly increases the diagnostic accuracy in an expert setting.
Comment in
-
HCCR-1 for detecting small hepatocellular carcinoma latent in a cirrhotic liver: a prospective cohort study.Gut. 2012 Oct;61(10):1514-5. doi: 10.1136/gutjnl-2012-301994. Epub 2012 Jul 31. Gut. 2012. PMID: 22851668 Free PMC article. No abstract available.
-
A meta-analysis for percutaneous tumour ablation in patients with small hepatocellular carcinoma: highlighting combined strategy in the future.Gut. 2013 Mar;62(3):477-8. doi: 10.1136/gutjnl-2012-303584. Epub 2012 Sep 26. Gut. 2013. PMID: 23013726 No abstract available.
-
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.Gut. 2013 Nov;62(11):1667-8. doi: 10.1136/gutjnl-2013-305164. Epub 2013 May 25. Gut. 2013. PMID: 23708586 Free PMC article. No abstract available.
-
Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies.Gut. 2013 Oct;62(10):1520-1. doi: 10.1136/gutjnl-2013-305231. Epub 2013 Aug 8. Gut. 2013. PMID: 23929696 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical